Welcome to our dedicated page for Stealth Biotherapeutics news (Ticker: MITO), a resource for investors and traders seeking the latest updates and insights on Stealth Biotherapeutics stock.
Stealth BioTherapeutics Corp (MITO) has been the subject of news coverage centered on its mitochondria-targeted drug pipeline, regulatory milestones, and corporate transactions. Historically described as a clinical-stage biotechnology company, Stealth has focused on developing therapies for diseases involving mitochondrial dysfunction in high-energy organs such as the heart, eye, neuromuscular system, and brain.
News about Stealth has included clinical and regulatory updates for its lead candidate elamipretide, including interactions with the U.S. Food & Drug Administration (FDA) regarding Barth syndrome and other indications. Earlier releases detailed pre-NDA discussions and long-term clinical data in Barth syndrome, while a later announcement from Stealth BioTherapeutics Inc. reported that FORZINITY (elamipretide) injection received accelerated approval from the FDA as the first treatment for Barth syndrome and the first FDA-approved mitochondria-targeted therapeutic.
Coverage has also highlighted the company’s second-generation candidate SBT-272, with Phase 1 safety and tolerability results and preclinical data in amyotrophic lateral sclerosis (ALS) and other neurodegenerative disease models. Stealth has reported Orphan Drug Designation for SBT-272 for the treatment of ALS and presented data at scientific conferences focused on ALS and neurodegenerative disease research.
Corporate and capital markets developments are another recurring theme. In 2022, Stealth issued multiple releases about a preliminary non-binding proposal, a definitive agreement for a going-private transaction, and the subsequent completion of a merger that resulted in the company becoming privately held and its ADSs being delisted from the Nasdaq Global Market. Earlier communications also addressed a Nasdaq non-compliance notice related to listing requirements.
Investors and researchers using this news page can review historical announcements on clinical progress, FDA designations and meetings, ultra-rare disease engagement, and the steps leading to Stealth’s transition from a Nasdaq-listed issuer under the MITO symbol to a privately held biotechnology company.
Stealth BioTherapeutics (Nasdaq: MITO) announced its participation in the 2020 American Society of Human Genetics (ASHG) Meeting, presenting a poster that received a "Reviewers' Choice" award for its significance. The poster highlights the TAZPOWER trial results, demonstrating that elamipretide significantly improves functional parameters in Barth syndrome compared to natural history controls. The interventional study showed statistically significant enhancements in exercise endurance and cardiac function in patients receiving elamipretide, highlighting its potential to address unmet medical needs in ultra-rare diseases.
Stealth BioTherapeutics (Nasdaq: MITO) announced its participation in the 2020 Annual NEALS Meeting, showcasing a poster awarded the UMN/PLS Poster Award. The poster presents data on SBT-272, highlighting its protective effects on upper motor neurons against TDP43 pathology, relevant to neurodegenerative diseases like ALS and Alzheimer's. SBT-272 is a mitochondrial-targeted peptidomimetic that enhances ATP production and reduces reactive oxygen species, demonstrating potential for treating various neurodegenerative conditions. Continued research on SBT-272 is planned following positive preclinical results.
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology firm, announced CEO Reenie McCarthy's presentations at three upcoming virtual investor conferences in September 2020. The conferences include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 4:30 pm ET, the Cantor Fitzgerald's Virtual Global Healthcare Conference on September 16 at 8:40 am ET, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23 at 1:40 pm ET. Live webcasts will be available on their website.
Stealth BioTherapeutics Corp (Nasdaq: MITO) reported its Q2 2020 financial results, highlighting a net loss of $12.4 million, improved from $15.8 million in Q2 2019. Cash and cash equivalents stood at $31.8 million. R&D expenses decreased to $7.4 million, reflecting strategic repositioning. The firm remains focused on advancing elamipretide for mitochondrial diseases, despite FDA recommendations for additional data prior to NDA submission. Phase 2b trial enrollment in dry AMD is over 75% complete, with full enrollment expected by year-end.
Stealth BioTherapeutics (Nasdaq: MITO) will report its second quarter 2020 financial results on August 6, 2020, before market opening. A conference call is scheduled for 8:30 am ET to discuss the results and provide a business update. The company focuses on developing therapies for mitochondrial dysfunction, with candidates like elamipretide for rare metabolic conditions and SBT-272 for neurodegenerative diseases such as ALS. Investors can access the call via telephone or webcast.